Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ataciguat. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 13/20 | 0.64 |
| ▸ | MEN1 | O00255 | 12/20 | 0.64 |
| ▸ | MAPT | P10636 | 7/20 | 0.64 |
| ▸ | HTT | P42858 | 5/20 | 0.64 |
| ▸ | LMNA | P02545 | 5/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
| ▸ | F10 | P00742 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ataciguat SCHEMBL29370450 | 1.00 | KMT2A (0.64) | KMT2AMEN1MAPTHTTLMNA | |
| Ataciguat SCHEMBL492158 | 0.99 | KMT2A (0.63) | KMT2AMEN1MAPTHTTLMNA | |
| SCHEMBL13297364 | 0.91 | KMT2A (0.62) | KMT2AMEN1MAPTHTTLMNA | |
| SCHEMBL10252896 | 0.91 | ALDH1A1 (0.58) | KMT2AMEN1MAPTHTTLMNA | |
| SCHEMBL29424222 | 0.89 | KMT2A (0.76) | KMT2AMEN1MAPTHTTLMNA | |
| SCHEMBL492486 | 0.89 | KMT2A (0.59) | KMT2AMEN1MAPTHTTLMNA | |
| SCHEMBL491931 | 0.88 | KMT2A (0.72) | KMT2AMEN1MAPTHTTLMNA | |
| SCHEMBL491936 | 0.87 | KMT2A (0.61) | KMT2AMEN1MAPTHTTLMNA | |
| SCHEMBL491874 | 0.87 | KMT2A (0.63) | KMT2AMEN1MAPTHTTLMNA | |
| SCHEMBL492533 | 0.86 | KMT2A (0.60) | KMT2AMEN1MAPTHTTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 146 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220211702-A1 | METHODS AND MATERIALS FOR GENDER-DEPENDENT TREATMENT OF CARDIOVASCULAR DYSFUNCTION | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH | 2022-07-07 | — | — | US | claimed |
| EP-3952992-A1 | METHODS AND MATERIALS FOR GENDER-DEPENDENT TREATMENT OF CARDIOVASCULAR DYSFUNCTION | Mayo Foundation for Medical Education and Research (US) | 2022-02-16 | — | — | EP | claimed |
| WO-2020210707-A1 | METHODS AND MATERIALS FOR GENDER-DEPENDENT TREATMENT OF CARDIOVASCULAR DYSFUNCTION | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2020-10-15 | — | — | WO | claimed |
| US-9789126-B2 | Methods and materials for treating calcific aortic valve stenosis | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2017-10-17 | — | — | US | claimed |
| EP-2207541-B1 | USE OF SULFONYL-SUBSTITUTED 2-SULFONYLAMINOBENZOIC ACID N-PHENYLAMIDES IN THE TREATMENT OF PAIN | SANOFI AVENTIS DEUTSCHLAND (DE) | 2014-10-29 | — | — | EP | claimed |
| US-8518998-B2 | Use of sulfonyl-substituted 2-sulfonylaminobenzoic acid N-phenylamides in the treatment of pain | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2013-08-27 | — | — | US | claimed |
| US-20120108573-A1 | SULFUR SUBSTITUTED SULFONYLAMINOCARBOXYLIC ACID N-ARYLAMIDES, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM | SANOFI-AVENTIS DEUTSCHLAND GMBH | 2012-05-03 | — | — | US | claimed |
| US-8106213-B2 | For example, 2-(4-chloro-phenylsulfonylamino)-4,5-dimethoxy-N-(4-(thiomorpholine-4-sulfonyl)-phenyl)-benzamide; for therapy and prophylaxis of cardiovascular diseases such as hypertension, angina pectoris, cardiac insufficiency, thromboses or atherosclerosis | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2012-01-31 | — | — | US | claimed |
| US-20110021505-A1 | Use of sulfonyl-substituted 2-sulfonylaminobenzoic acid N-phenylamides in the treatment of pain | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2011-01-27 | — | — | US | claimed |
| EP-2207541-A1 | USE OF SULFONYL-SUBSTITUTED 2-SULFONYLAMINOBENZOIC ACID N-PHENYLAMIDES IN THE TREATMENT OF PAIN | Sanofi-Aventis Deutschland GmbH (DE) | 2010-07-21 | — | — | EP | claimed |
| WO-2009043495-A1 | USE OF SULFONYL-SUBSTITUTED 2-SULFONYLAMINOBENZOIC ACID N-PHENYLAMIDES IN THE TREATMENT OF PAIN | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-04-09 | — | — | WO | claimed |
| US-20080096936-A1 | Sulfur substituted sulfonylaminocarboxylic acid N-arylamides, their preparation, their use and pharmaceutical preparations comprising them | TELEVOX SOFTWARE, INCORPORATED | 2008-04-24 | — | — | US | claimed |
| EP-1095016-B1 | SULFUR SUBSTITUTED SULFONYLAMINOCARBOXYLIC ACID N-ARYLAMIDES, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM | SANOFI AVENTIS DEUTSCHLAND (DE) | 2005-11-09 | — | — | EP | claimed |
| WO-2005042022-A2 | COMBINATION OF AN ACTIVATOR OF SOLUBLEGUANYLATE CYCLASE AND AN ANGIOTENSIN II RECEPTOR ANTAGONIST | PFIZER LIMITED (GB) | 2005-05-12 | — | — | WO | claimed |
| US-20050059660-A1 | activators of soluble guanylate cyclase, and inhibitors of angiotensin converting enzyme such as benazepril; treatment of cardiovascular or metabolic disorders | PHARMACIA & UPJOHN COMPANY | 2005-03-17 | — | — | US | claimed |
| WO-2005011727-A1 | COMBINATION OF AN ACTIVATOR OF SOLUBLE GUANYLATE CYCLASE AND AN ACE-INHIBITOR FOR THE TREATMENT OF A CARDIOVASCULAR OR METABOLIC DISORDER | PFIZER LIMITED (GB) | 2005-02-10 | — | — | WO | claimed |
| US-20040186145-A1 | Sulfur substituted sulfonylaminocarboxylic acid N-arylamides, their preparation, their use and pharmaceutical preparations comprising them | AVENTIS PHARMA DEUTSCHLAND GMBH. | 2004-09-23 | — | — | US | claimed |
| US-20020061887-A1 | Sulfur substituted sulfonylaminocarboxylic acid N-arylamides, their preparation, their use and pharmaceutical preparations comprising them | AVENTIS PHARMA DEUTSCHLAND GMBH | 2002-05-23 | — | — | US | claimed |
| US-6335334-B1 | HYPERTENSIVE AGENTS, ANTICOAGULANTS; CARDIOVASCULAR AND SEXUAL DISORDERS, ANGINA PECTORIS, AND ATHEROSCLEROSIS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-01-01 | — | — | US | claimed |
| US-12465605-B2 | Methods and materials for gender-dependent treatment of cardiovascular dysfunction | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2025-11-11 | — | — | US | disclosed |
| EP-3538096-B1 | TREATMENT OF CNS DISEASES WITH SGC STIMULATORS | TISENTO THERAPEUTICS INC (US) | 2024-02-28 | — | — | EP | disclosed |
| US-20230381153-A1 | TREATMENT OF CNS DISEASES WITH sGC STIMULATORS | TISENTO THERAPEUTICS INC. | 2023-11-30 | — | — | US | disclosed |
| EP-3998260-B1 | SGC STIMULATORS | CYCLERION THERAPEUTICS INC (US) | 2023-11-01 | — | — | EP | disclosed |
| US-11731977-B2 | SGC stimulators | CYCLERION THERAPEUTICS, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| EP-3872080-B1 | FUSED BICYCLIC SGC STIMULATORS | CYCLERION THERAPEUTICS INC (US) | 2023-08-16 | — | — | EP | disclosed |
| US-11690828-B2 | Treatment of CNS diseases with sGC stimulators | CYCLERION THERAPEUTICS, INC. (US) | 2023-07-04 | — | — | US | disclosed |
| WO-2023018795-A1 | NEP INHIBITORS FOR THE TREATMENT OF LAMINITIS | CURTAILS LLC (US) | 2023-02-16 | — | — | WO | disclosed |
| US-11572358-B2 | Solid forms of an sGC stimulator | CYCLERION THERAPEUTICS, INC. (US) | 2023-02-07 | — | — | US | disclosed |
| US-20220211702-A1 | METHODS AND MATERIALS FOR GENDER-DEPENDENT TREATMENT OF CARDIOVASCULAR DYSFUNCTION | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH | 2022-07-07 | — | — | US | disclosed |
| US-11357777-B2 | Use of sGC stimulators for the treatment of nonalcoholic steatohepatitis (NASH) | CYCLERION THERAPEUTICS, INC. (US) | 2022-06-14 | — | — | US | disclosed |
| EP-3411026-B1 | USE OF STIMULATORS OF SOLUBLE GUANYLATE CYCLASE FOR THE TREATMENT OF NONALCOHOLIC STEATOHEPATITIS (NASH) | CYCLERION THERAPEUTICS INC (US) | 2022-03-09 | — | — | EP | disclosed |
| US-20220062307-A1 | METHODS AND MATERIALS FOR TREATING CALCIFIC AORTIC VALVE STENOSIS | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2022-03-03 | — | — | US | disclosed |
| EP-3952992-A1 | METHODS AND MATERIALS FOR GENDER-DEPENDENT TREATMENT OF CARDIOVASCULAR DYSFUNCTION | Mayo Foundation for Medical Education and Research (US) | 2022-02-16 | — | — | EP | disclosed |
| US-20220023246-A1 | STIMULATORS AND/OR ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE (SGC) IN COMBINATION WITH AN INHIBITOR OF NEUTRAL ENDOPEPTIDASE (NEP INHIBITOR) AND/OR AN ANGIOTENSIN AII ANTAGONIST AND THE USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-01-27 | — | — | US | disclosed |
| US-20220017515-A1 | sGC STIMULATORS | TISENTO THERAPEUTICS INC. | 2022-01-20 | — | — | US | disclosed |
| US-20220009937-A1 | sGC STIMULATORS | TISENTO THERAPEUTICS INC. | 2022-01-13 | — | — | US | disclosed |
| US-11207323-B2 | sGC stimulators | CYCLERION THERAPEUTICS, INC. (US) | 2021-12-28 | — | — | US | disclosed |
| US-11180493-B2 | SGC stimulators | CYCLERION THERAPEUTICS, INC. (US) | 2021-11-23 | — | — | US | disclosed |
| US-11166932-B2 | Stimulators and/or activators of soluble guanylate cyclase (sGC) in combination with an inhibitor of neutral endopeptidase (NEP inhibitor) and/or an angiotensin AII antagonist and the use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-11-09 | — | — | US | disclosed |
| US-20210214364-A1 | sGC STIMULATORS | CYCLERION THERAPEUTICS INC (US) | 2021-07-15 | — | — | US | disclosed |
| US-20210188830-A1 | SOLID FORMS OF AN SGC STIMULATOR | CYCLERION THERAPEUTICS, INC. | 2021-06-24 | — | — | US | disclosed |
| US-20210161893-A1 | USE OF sGC STIMULATORS FOR THE TREATMENT OF NONALCOHOLIC STEATOHEPATITIS (NASH) | CYCLERION THERAPEUTICS, INC. | 2021-06-03 | — | — | US | disclosed |
| EP-3507291-B1 | FUSED BICYCLIC SGC STIMULATORS | CYCLERION THERAPEUTICS INC (US) | 2021-05-26 | — | — | EP | disclosed |
| US-20210087198-A1 | sGC STIMULATORS | TISENTO THERAPEUTICS INC. | 2021-03-25 | — | — | US | disclosed |
| US-10927136-B2 | Phosphorus prodrugs of pyrazolo-substituted pyrimidine sGC stimulators | CYCLERION THERAPEUTICS, INC. (US) | 2021-02-23 | — | — | US | disclosed |
| US-10889577-B2 | Solid forms of an sGC stimulator | CYCLERION THERAPEUTICS, INC. (US) | 2021-01-12 | — | — | US | disclosed |
| US-10858363-B2 | SGC stimulators | CYCLERION THERAPEUTICS, INC. (US) | 2020-12-08 | — | — | US | disclosed |
| US-10844064-B2 | sGC stimulators | CYCLERION THERAPEUTICS, INC. (US) | 2020-11-24 | — | — | US | disclosed |
| WO-2020210707-A1 | METHODS AND MATERIALS FOR GENDER-DEPENDENT TREATMENT OF CARDIOVASCULAR DYSFUNCTION | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2020-10-15 | — | — | WO | disclosed |
| US-20200316065-A1 | sGC STIMULATORS | CYCLERION THERAPEUTICS, INC. | 2020-10-08 | — | — | US | disclosed |
| EP-3325013-B1 | STIMULATORS / ACTIVATORS OF SOLUBLE GUANYLAT CYCLASE IN COMBINATION WITH A NEP-INHIBITOR AND/OR AN ANGIOTENSIN AII-ANTAGONIST AND THE USE THEREOF | Bayer Pharma AG (DE) | 2020-09-23 | — | — | EP | disclosed |
| US-10639308-B2 | sGC stimulators | CYCLERION THERAPEUTICS, INC. (US) | 2020-05-05 | — | — | US | disclosed |
| US-20200071318-A1 | SGC STIMULATORS | TISENTO THERAPEUTICS INC. | 2020-03-05 | — | — | US | disclosed |
| US-20190345130-A1 | SGC STIMULATORS | CYCLERION THERAPEUTICS, INC. | 2019-11-14 | — | — | US | disclosed |
| US-20190343813-A1 | TREATMENT OF CNS DISEASES WITH sGC STIMULATORS | CYCLERION THERAPEUTICS, INC. (US) | 2019-11-14 | — | — | US | disclosed |
| US-10472363-B2 | SGC stimulators | CYCLERION THERAPEUTICS, INC. (US) | 2019-11-12 | — | — | US | disclosed |
| US-20190300555-A1 | PHOSPHORUS PRODRUGS OF SGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. | 2019-10-03 | — | — | US | disclosed |
| US-20190284168-A1 | PYRAZOLE DERIVATIES AS SGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC | 2019-09-19 | — | — | US | disclosed |
| US-20190248794-A1 | sGC STIMULATORS | TISENTO THERAPEUTICS INC. | 2019-08-15 | — | — | US | disclosed |
| EP-3291811-B1 | THE USE OF SGC STIMULATORS, SGC ACTIVATORS, ALONE AND COMBINATIONS WITH PDE5 INHIBITORS FOR THE TREATMENT OF DIGITAL ULCERS (DU) CONCOMITANT TO SYSTEMIC SCLEROSIS (SSC) | Bayer Pharma AG (DE) | 2019-08-07 | — | — | EP | disclosed |
| US-20190167679-A1 | sGC STIMULATORS | CYCLERION THERAPEUTICS, INC. | 2019-06-06 | — | — | US | disclosed |
| US-20190169179-A1 | SOLID FORMS OF AN SGC STIMULATOR | IRONWOOD PHARMACEUTICALS, INC. | 2019-06-06 | — | — | US | disclosed |
| US-20190125709-A1 | STIMULATORS AND/OR ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE (SGC) IN COMBINATION WITH AN INHIBITOR OF NEUTRAL ENDOPEPTIDASE (NEP INHIBITOR) AND/OR AN ANGIOTENSIN AII ANTAGONIST AND THE USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-05-02 | — | — | US | disclosed |
| US-10265314-B2 | SGC stimulators in combination with additional treatment for the therapy of cystic fibrosis | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-04-23 | — | — | US | disclosed |
| US-20190031641-A1 | PYRAZOLE DERIVATIVES AS SGC STIMULATORS | CYCLERION THERAPEUTICS, INC. | 2019-01-31 | — | — | US | disclosed |
| US-10189809-B2 | SGC stimulators | IRONWOOD PHARMACEUTICALS, INC. (US) | 2019-01-29 | — | — | US | disclosed |
| US-10189856-B2 | Use of sGC stimulators, sGC activators, alone and combinations with PDE5 inhibitors for the treatment of systemic sclerosis (SSc) | ADVERIO PHARMA GMBH (DE) | 2019-01-29 | — | — | US | disclosed |
| US-10183021-B2 | sGC stimulators | IRONWOOD PHARMACEUTICALS, INC. (US) | 2019-01-22 | — | — | US | disclosed |
| WO-2018153899-A1 | SELECTIVE PARTIAL ADENOSINE A1 RECEPTOR AGONISTS IN COMBINATION WITH SOLUBLE GUANYLYL CYCLASE (SGC) STIMULATORS AND/OR ACTIVATORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-08-30 | — | — | WO | disclosed |
| EP-3092231-B1 | SGC STIMULATORS | IRONWOOD PHARMACEUTICALS INC (US) | 2018-06-27 | — | — | EP | disclosed |
| US-20180169095-A1 | THE USE OF SGC STIMULATORS, SGC ACTIVATORS, ALONE AND COMBINATIONS WITH PDE5 INHIBITORS FOR THE TREATMENT OF DIGITAL ULCERS (DU) CONCOMITANT TO SYSTEMIC SCLEROSIS (SSC) | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-06-21 | — | — | US | disclosed |
| US-20180169095-A1 | THE USE OF SGC STIMULATORS, SGC ACTIVATORS, ALONE AND COMBINATIONS WITH PDE5 INHIBITORS FOR THE TREATMENT OF DIGITAL ULCERS (DU) CONCOMITANT TO SYSTEMIC SCLEROSIS (SSC) | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-06-21 | — | — | US | disclosed |
| WO-2018111795-A2 | USE OF SGC STIMULATORS FOR THE TREATMENT OF ESOPHAGEAL MOTILITY DISORDERS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2018-06-21 | — | — | WO | disclosed |
| US-20180155345-A1 | sGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2018-06-07 | — | — | US | disclosed |
| WO-2018089330-A2 | SGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2018-05-17 | — | — | WO | disclosed |
| WO-2018089328-A1 | TREATMENT OF CNS DISEASES WITH SGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2018-05-17 | — | — | WO | disclosed |
| WO-2018045276-A1 | FUSED BICYCLIC SGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2018-03-08 | — | — | WO | disclosed |
| US-20180065971-A1 | sGC STIMULATORS | TISENTO THERAPEUTICS INC. | 2018-03-08 | — | — | US | disclosed |
| US-20170305878-A1 | sGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2017-10-26 | — | — | US | disclosed |
| US-20170298055-A1 | sGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2017-10-19 | — | — | US | disclosed |
| US-20170291889-A1 | PYRAZOLE DERIVATIVES AS SGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2017-10-12 | — | — | US | disclosed |
| US-20170291902-A1 | sGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2017-10-12 | — | — | US | disclosed |
| WO-2017136309-A1 | USE OF sGC STIMULATORS FOR THE TREATMENT OF NONALCOHOLIC STEATOHEPATITIS (NASH) | IRONWOOD PHARMACEUTICALS, INC. (US) | 2017-08-10 | — | — | WO | disclosed |
| US-20170136019-A1 | sGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2017-05-18 | — | — | US | disclosed |
| US-20170112845-A1 | sGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2017-04-27 | — | — | US | disclosed |
| US-20170065586-A1 | SGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2017-03-09 | — | — | US | disclosed |
| US-9586937-B2 | sGC stimulators | IRONWOOD PHARMACEUTICALS, INC. (US) | 2017-03-07 | — | — | US | disclosed |
| WO-2017013010-A1 | STIMULATORS AND/OR ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE (SGC) IN COMBINATION WITH AN INHIBITOR OF NEUTRAL ENDOPEPTIDASE (NEP INHIBITOR) AND/OR AN ANGIOTENSIN AII ANTAGONIST AND THE USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-01-26 | — | — | WO | disclosed |
| US-20160347738-A1 | sGC STIMULATORS | CYCLERION THERAPEUTICS, INC. | 2016-12-01 | — | — | US | disclosed |
| US-20160324856-A1 | USE OF SGC STIMULATORS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS | CYCLERION THERAPEUTICS, INC. | 2016-11-10 | — | — | US | disclosed |
| US-9487508-B2 | SGC stimulators | IRONWOOD PHARMACEUTICALS, INC. (US) | 2016-11-08 | — | — | US | disclosed |
| US-9481689-B2 | sGC stimulators | IRONWOOD PHARMACEUTICALS, INC. (US) | 2016-11-01 | — | — | US | disclosed |
| US-20160311826-A1 | SGC STIMULATORS | CYCLERION THERAPEUTICS, INC. | 2016-10-27 | — | — | US | disclosed |
| US-20160175307-A1 | sGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2016-06-23 | — | — | US | disclosed |
| US-20160158233-A1 | SGC STIMULATORS OR SGC ACTIVATORS AND PDE5 INHIBITORS IN COMBINATION WITH ADDITIONAL TREATMENT FOR THE THERAPY OF CYSTIC FIBROSIS | BAYER PHARMA AKTIENGESELl SCHAFT (DE) | 2016-06-09 | — | — | US | disclosed |
| US-20160158233-A1 | SGC STIMULATORS OR SGC ACTIVATORS AND PDE5 INHIBITORS IN COMBINATION WITH ADDITIONAL TREATMENT FOR THE THERAPY OF CYSTIC FIBROSIS | BAYER PHARMA AKTIENGESELl SCHAFT (DE) | 2016-06-09 | — | — | US | disclosed |
| US-20160031903-A1 | sGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2016-02-04 | — | — | US | disclosed |
| US-20150342954-A1 | 2-BENZYL, 3-(PYRIMIDIN-2-YL) SUBSTITUTED PYRAZOLES USEFUL AS SGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2015-12-03 | — | — | US | disclosed |
| US-9139564-B2 | 2-benzyl, 3-(pyrimidin-2-yl) substituted pyrazoles useful as sGC stimulators | IRONWOOD PHARMACEUTICALS, INC. (US) | 2015-09-22 | — | — | US | disclosed |
| US-20150250795-A1 | sGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2015-09-10 | — | — | US | disclosed |
| US-20150232461-A1 | SGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2015-08-20 | — | — | US | disclosed |
| US-9024069-B2 | NONOate derivatives and uses thereof | IRONWOOD PHARMACEUTICALS, INC. (US) | 2015-05-05 | — | — | US | disclosed |
| US-20140323448-A1 | sGC STIMULATORS | Ironwood Pharmaceuticals Inc. (US) | 2014-10-30 | — | — | US | disclosed |
| EP-2207541-B1 | USE OF SULFONYL-SUBSTITUTED 2-SULFONYLAMINOBENZOIC ACID N-PHENYLAMIDES IN THE TREATMENT OF PAIN | SANOFI AVENTIS DEUTSCHLAND (DE) | 2014-10-29 | — | — | EP | disclosed |
| US-20140288079-A1 | SGC STIMULATORS OF SGC ACTIVATORS IN COMBINATION WITH PDE5 INHBITORS FOR THE TREATMENT OF ERECTILE DYSFUNCTION | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-09-25 | — | — | US | disclosed |
| US-20140288079-A1 | SGC STIMULATORS OF SGC ACTIVATORS IN COMBINATION WITH PDE5 INHBITORS FOR THE TREATMENT OF ERECTILE DYSFUNCTION | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-09-25 | — | — | US | disclosed |
| US-8748442-B2 | sGC stimulators | IRONWOOD PHARMACEUTICALS, INC. (US) | 2014-06-10 | — | — | US | disclosed |
| US-20140135295-A1 | NONOATE DERIVATIVES AND USES THEREOF | IRONWOOD PHARMACEUTICALS (US) | 2014-05-15 | — | — | US | disclosed |
| US-20140038956-A1 | Use of sGC stimulators, sGC activators, alone and combinations with PDE5 inhibitors for the treatment of systemic sclerosis (SSc). | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-02-06 | — | — | US | disclosed |
| US-20140038956-A1 | Use of sGC stimulators, sGC activators, alone and combinations with PDE5 inhibitors for the treatment of systemic sclerosis (SSc). | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-02-06 | — | — | US | disclosed |
| US-8541410-B2 | Sulfur substituted sulfonylaminocarboxylic acid N-arylamides, their preparation, their use and pharmaceutical preparations comprising them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2013-09-24 | — | — | US | disclosed |
| US-8518998-B2 | Use of sulfonyl-substituted 2-sulfonylaminobenzoic acid N-phenylamides in the treatment of pain | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2013-08-27 | — | — | US | disclosed |
| US-20130178475-A1 | sGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2013-07-11 | — | — | US | disclosed |
| US-20130158028-A1 | USE OF STIMULATORS AND ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE FOR TREATING SICKLE-CELL ANEMIA AND CONSERVING BLOOD SUBSTITUTES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-06-20 | — | — | US | disclosed |
| US-20130158028-A1 | USE OF STIMULATORS AND ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE FOR TREATING SICKLE-CELL ANEMIA AND CONSERVING BLOOD SUBSTITUTES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-06-20 | — | — | US | disclosed |
| US-20130158028-A1 | USE OF STIMULATORS AND ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE FOR TREATING SICKLE-CELL ANEMIA AND CONSERVING BLOOD SUBSTITUTES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-06-20 | — | — | US | disclosed |
| US-8461348-B2 | Heterocyclic derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-06-11 | — | — | US | disclosed |
| US-8461348-B2 | Heterocyclic derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-06-11 | — | — | US | disclosed |
| US-20130123354-A1 | SOLUBLE GUANYLATE CYCLASE (SGC) MODULATORS FOR TREATMENT OF LIPID RELATED DISORDERS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2013-05-16 | — | — | US | disclosed |
| US-20130035340-A1 | sGC STIMULATORS OR sGC ACTIVATORS ALONE AND IN COMBINATION WITH PDE5 INHBITORS FOR THE TREATMENT OF CYSTIC FIBROSIS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-02-07 | — | — | US | disclosed |
| US-20120108573-A1 | SULFUR SUBSTITUTED SULFONYLAMINOCARBOXYLIC ACID N-ARYLAMIDES, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM | SANOFI-AVENTIS DEUTSCHLAND GMBH | 2012-05-03 | — | — | US | disclosed |
| US-8106213-B2 | For example, 2-(4-chloro-phenylsulfonylamino)-4,5-dimethoxy-N-(4-(thiomorpholine-4-sulfonyl)-phenyl)-benzamide; for therapy and prophylaxis of cardiovascular diseases such as hypertension, angina pectoris, cardiac insufficiency, thromboses or atherosclerosis | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2012-01-31 | — | — | US | disclosed |
| US-20120022028-A1 | SGC STIMULATORS OR SGC ACTIVATORS IN COMBINATION WITH PDE5 INHIBITORS FOR THE TREATMENT OF ERECTILE DYSFUNCTION | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-01-26 | — | — | US | disclosed |
| US-20110159474-A1 | SOLUTIONS FOR PERFUSING AND PRESERVING ORGANS AND TISSUES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-06-30 | — | — | US | disclosed |
| US-20110028493-A1 | HETEROCYCLIC DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-02-03 | — | — | US | disclosed |
| US-20110028493-A1 | HETEROCYCLIC DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-02-03 | — | — | US | disclosed |
| US-20110021505-A1 | Use of sulfonyl-substituted 2-sulfonylaminobenzoic acid N-phenylamides in the treatment of pain | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2011-01-27 | — | — | US | disclosed |
| WO-2010081647-A2 | SGC STIMULATORS OF SGC ACTIVATORS IN COMBINATION WITH PDE5 INHBITORS FOR THE TREATMENT OF ERECTILE DYSFUNCTION | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-07-22 | — | — | WO | disclosed |
| EP-2207541-A1 | USE OF SULFONYL-SUBSTITUTED 2-SULFONYLAMINOBENZOIC ACID N-PHENYLAMIDES IN THE TREATMENT OF PAIN | Sanofi-Aventis Deutschland GmbH (DE) | 2010-07-21 | — | — | EP | disclosed |
| US-20100016305-A1 | novel use of activators and stimulators of soluble guanylate cyclase for the prevention or treatment of renal disorders | BAYER HEALTHCARE AG (DE) | 2010-01-21 | — | — | US | disclosed |
| US-20090221573-A1 | Use of Activators of Soluble Guanylate Cyclase for Promoting Wound Healing | BAYER HEALTHCARE AG (DE) | 2009-09-03 | — | — | US | disclosed |
| WO-2009043495-A1 | USE OF SULFONYL-SUBSTITUTED 2-SULFONYLAMINOBENZOIC ACID N-PHENYLAMIDES IN THE TREATMENT OF PAIN | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-04-09 | — | — | WO | disclosed |
| US-20080096936-A1 | Sulfur substituted sulfonylaminocarboxylic acid N-arylamides, their preparation, their use and pharmaceutical preparations comprising them | TELEVOX SOFTWARE, INCORPORATED | 2008-04-24 | — | — | US | disclosed |
| US-7326789-B2 | Sulfur substituted sulfonylaminocarboxylic acid N-arylamides, their preparation, their use and pharmaceutical preparations comprising them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-02-05 | — | — | US | disclosed |
| WO-2007009607-A1 | NOVEL USE OF ACTIVATORS AND STIMULATORS OF SOLUBLE GUANYLATE CYCLASE FOR THE PREVENTION OR TREATMENT OF RENAL DISORDERS | BAYER HEALTHCARE AG (DE) | 2007-01-25 | — | — | WO | disclosed |
| EP-1614678-A2 | Sulfur substituted sulfonylaminocarboxylic acid N-heteroarylamides, their preparation, their use and pharmaceutical preparations comprising them | Sanofi-Aventis Deutschland GmbH (DE) | 2006-01-11 | — | — | EP | disclosed |
| EP-1095016-B1 | SULFUR SUBSTITUTED SULFONYLAMINOCARBOXYLIC ACID N-ARYLAMIDES, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM | SANOFI AVENTIS DEUTSCHLAND (DE) | 2005-11-09 | — | — | EP | disclosed |
| WO-2005042022-A2 | COMBINATION OF AN ACTIVATOR OF SOLUBLEGUANYLATE CYCLASE AND AN ANGIOTENSIN II RECEPTOR ANTAGONIST | PFIZER LIMITED (GB) | 2005-05-12 | — | — | WO | disclosed |
| US-6881735-B2 | Sulfur substituted sulfonylaminocarboxylic acid N-arylamides, their preparation, their use and pharmaceutical preparations comprising them | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-04-19 | — | — | US | disclosed |
| US-20050059660-A1 | activators of soluble guanylate cyclase, and inhibitors of angiotensin converting enzyme such as benazepril; treatment of cardiovascular or metabolic disorders | PHARMACIA & UPJOHN COMPANY | 2005-03-17 | — | — | US | disclosed |
| WO-2005011727-A1 | COMBINATION OF AN ACTIVATOR OF SOLUBLE GUANYLATE CYCLASE AND AN ACE-INHIBITOR FOR THE TREATMENT OF A CARDIOVASCULAR OR METABOLIC DISORDER | PFIZER LIMITED (GB) | 2005-02-10 | — | — | WO | disclosed |
| US-20040186145-A1 | Sulfur substituted sulfonylaminocarboxylic acid N-arylamides, their preparation, their use and pharmaceutical preparations comprising them | AVENTIS PHARMA DEUTSCHLAND GMBH. | 2004-09-23 | — | — | US | disclosed |
| US-20020061887-A1 | Sulfur substituted sulfonylaminocarboxylic acid N-arylamides, their preparation, their use and pharmaceutical preparations comprising them | AVENTIS PHARMA DEUTSCHLAND GMBH | 2002-05-23 | — | — | US | disclosed |
| US-6335334-B1 | HYPERTENSIVE AGENTS, ANTICOAGULANTS; CARDIOVASCULAR AND SEXUAL DISORDERS, ANGINA PECTORIS, AND ATHEROSCLEROSIS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-01-01 | — | — | US | disclosed |
| EP-1095016-A1 | SULFUR SUBSTITUTED SULFONYLAMINOCARBOXYLIC ACID N-ARYLAMIDES, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM | Aventis Pharma Deutschland GmbH (DE) | 2001-05-02 | — | — | EP | disclosed |
| WO-2000002851-A1 | SULFUR SUBSTITUTED SULFONYLAMINOCARBOXYLIC ACID N-ARYLAMIDES, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2000-01-20 | — | — | WO | disclosed |
| WO-2000002851-A1 | SULFUR SUBSTITUTED SULFONYLAMINOCARBOXYLIC ACID N-ARYLAMIDES, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2000-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200071318-A1 | SGC STIMULATORS | GUCY1A2, GMPS, PDE2A | KMT2A 4675/4885MEN1 4141/4885MAPT 4780/4885 |
| US-20130035340-A1 | sGC STIMULATORS OR sGC ACTIVATORS ALONE AND IN COMBINATION WITH PDE5 INHBITORS FOR THE TREATMENT OF CYSTIC FIBROSIS | PDE5A, PDE3B, PDE3A | KMT2A 4107/4885MEN1 4037/4885MAPT 4882/4885 |
| US-20140038956-A1 | Use of sGC stimulators, sGC activators, alone and combinations with PDE5 inhibitors for the treatment of systemic sclerosis (SSc). | PDE5A, PDE3A, PDE2A | KMT2A 4077/4885MEN1 4083/4885MAPT 4843/4885 |
| US-20140323448-A1 | sGC STIMULATORS | GUCY1A1, PTGIS, GUCY1B1 | KMT2A 4149/4885MEN1 3461/4885MAPT 4837/4885 |
| US-20120108573-A1 | SULFUR SUBSTITUTED SULFONYLAMINOCARBOXYLIC ACID N-ARYLAMIDES, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM | GUCY1A1, GUCY1B1, GUCY1A2 | KMT2A 4155/4885MEN1 2028/4885MAPT 4863/4885 |
| US-20160324856-A1 | USE OF SGC STIMULATORS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS | SMN1; SMN2, PRKG1, GUCY1A2 | KMT2A 4060/4885MEN1 2619/4885MAPT 4292/4885 |
| US-10889577-B2 | Solid forms of an sGC stimulator | GUCY1A2, PRKG1, GUCY1A1 | KMT2A 4389/4885MEN1 2771/4885MAPT 4405/4885 |
| US-20110021505-A1 | Use of sulfonyl-substituted 2-sulfonylaminobenzoic acid N-phenylamides in the treatment of pain | SCN1A, SCN2A, CACNA1A | KMT2A 568/4885MEN1 3830/4885MAPT 4467/4885 |
| US-20190343813-A1 | TREATMENT OF CNS DISEASES WITH sGC STIMULATORS | GUCY1A2, GUCY1B2, PDE2A | KMT2A 3687/4885MEN1 1983/4885MAPT 3160/4885 |
| US-20220017515-A1 | sGC STIMULATORS | GUCY1A2, PRKG1, PDE2A | KMT2A 4673/4885MEN1 4168/4885MAPT 4786/4885 |
| US-20150250795-A1 | sGC STIMULATORS | PTGIS, GUCY1B1, GUCY1A1 | KMT2A 4155/4885MEN1 3580/4885MAPT 4845/4885 |
| US-20100016305-A1 | novel use of activators and stimulators of soluble guanylate cyclase for the prevention or treatment of renal disorders | GUCY1A2, GUCY1A1, GUCY1B2 | KMT2A 4447/4885MEN1 2374/4885MAPT 4836/4885 |
| US-20180169095-A1 | THE USE OF SGC STIMULATORS, SGC ACTIVATORS, ALONE AND COMBINATIONS WITH PDE5 INHIBITORS FOR THE TREATMENT OF DIGITAL ULCERS (DU) CONCOMITANT TO SYSTEMIC SCLEROSIS (SSC) | PDE5A, PDE2A, PDE3A | KMT2A 3871/4885MEN1 4593/4885MAPT 4858/4885 |
| US-10472363-B2 | SGC stimulators | GUCY1A2, PRKG1, GMPS | KMT2A 4533/4885MEN1 4282/4885MAPT 4733/4885 |
| US-20210087198-A1 | sGC STIMULATORS | GUCY1A2, PRKG1, GMPS | KMT2A 4533/4885MEN1 4282/4885MAPT 4733/4885 |
| US-10858363-B2 | SGC stimulators | GUCY1A2, PRKG1, GMPS | KMT2A 4533/4885MEN1 4282/4885MAPT 4733/4885 |
| US-20170291889-A1 | PYRAZOLE DERIVATIVES AS SGC STIMULATORS | PTGIS, GMPS, NOS3 | KMT2A 3988/4885MEN1 3903/4885MAPT 4697/4885 |
| US-20190284168-A1 | PYRAZOLE DERIVATIES AS SGC STIMULATORS | PTGIS, GMPS, NOS3 | KMT2A 3612/4885MEN1 3871/4885MAPT 4703/4885 |
| US-20170305878-A1 | sGC STIMULATORS | GUCY1A1, PTGIS, GUCY1B1 | KMT2A 4149/4885MEN1 3461/4885MAPT 4837/4885 |
| US-20130158028-A1 | USE OF STIMULATORS AND ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE FOR TREATING SICKLE-CELL ANEMIA AND CONSERVING BLOOD SUBSTITUTES | PDE5A, GUCY1A1, PDE2A | KMT2A 3246/4885MEN1 2710/4885MAPT 4850/4885 |
| US-20140135295-A1 | NONOATE DERIVATIVES AND USES THEREOF | SLC10A1, NOTUM, FASTKD5 | KMT2A 3608/4885MEN1 1038/4885MAPT 2970/4885 |
| US-20130178475-A1 | sGC STIMULATORS | GUCY1A1, PTGIS, GUCY1B1 | KMT2A 4149/4885MEN1 3461/4885MAPT 4837/4885 |
| US-11690828-B2 | Treatment of CNS diseases with sGC stimulators | GUCY1A2, GUCY1B2, PDE2A | KMT2A 3687/4885MEN1 1983/4885MAPT 3160/4885 |
| US-11207323-B2 | sGC stimulators | PTGIS, CGAS, GUCY1A1 | KMT2A 4250/4885MEN1 2447/4885MAPT 4849/4885 |
| US-20160158233-A1 | SGC STIMULATORS OR SGC ACTIVATORS AND PDE5 INHIBITORS IN COMBINATION WITH ADDITIONAL TREATMENT FOR THE THERAPY OF CYSTIC FIBROSIS | PDE5A, PDE3A, GMPS | KMT2A 4504/4885MEN1 4334/4885MAPT 4883/4885 |
| US-20170291902-A1 | sGC STIMULATORS | GUCY1B1, GUCY1A1, PRKG1 | KMT2A 2303/4885MEN1 3230/4885MAPT 4871/4885 |
| US-20190169179-A1 | SOLID FORMS OF AN SGC STIMULATOR | GUCY1A2, PRKG1, GUCY1A1 | KMT2A 4394/4885MEN1 2747/4885MAPT 4411/4885 |
| US-20170298055-A1 | sGC STIMULATORS | GUCY1B1, GUCY1A1, PRKG2 | KMT2A 3187/4885MEN1 3266/4885MAPT 4869/4885 |
| US-20160175307-A1 | sGC STIMULATORS | GUCY1A1, PTGIS, GUCY1B1 | KMT2A 4149/4885MEN1 3461/4885MAPT 4837/4885 |
| US-10639308-B2 | sGC stimulators | PTGIS, CGAS, GUCY1A1 | KMT2A 4250/4885MEN1 2447/4885MAPT 4849/4885 |
| US-10265314-B2 | SGC stimulators in combination with additional treatment for the therapy of cystic fibrosis | PDE5A, GMPS, PDE3A | KMT2A 4569/4885MEN1 4595/4885MAPT 4882/4885 |
| US-20160347738-A1 | sGC STIMULATORS | PTGIS, CGAS, GUCY1A1 | KMT2A 4250/4885MEN1 2447/4885MAPT 4849/4885 |
| US-20150232461-A1 | SGC STIMULATORS | GUCY1B1, GUCY1A1, PRKG1 | KMT2A 3461/4885MEN1 4477/4885MAPT 4855/4885 |
| US-20180065971-A1 | sGC STIMULATORS | GUCY1A2, PRKG1, GMPS | KMT2A 4533/4885MEN1 4282/4885MAPT 4733/4885 |
| US-20110159474-A1 | SOLUTIONS FOR PERFUSING AND PRESERVING ORGANS AND TISSUES | GUCY1A1, GUCY1A2, PDE3B | KMT2A 4626/4885MEN1 1506/4885MAPT 4645/4885 |
| US-20190300555-A1 | PHOSPHORUS PRODRUGS OF SGC STIMULATORS | PRKG1, PRKG2, P2RY1 | KMT2A 3243/4885MEN1 1824/4885MAPT 4856/4885 |
| US-20160311826-A1 | SGC STIMULATORS | GUCY1A1, GUCY1B1, GUCY1A2 | KMT2A 3344/4885MEN1 3637/4885MAPT 4863/4885 |
| US-20150342954-A1 | 2-BENZYL, 3-(PYRIMIDIN-2-YL) SUBSTITUTED PYRAZOLES USEFUL AS SGC STIMULATORS | PTGIS, PDE3B, GMPS | KMT2A 3914/4885MEN1 3284/4885MAPT 4801/4885 |
| US-20110028493-A1 | HETEROCYCLIC DERIVATIVE AND USE THEREOF | PDE3B, PDE5A, PDE2A | KMT2A 3197/4885MEN1 2661/4885MAPT 4667/4885 |
| US-20040186145-A1 | Sulfur substituted sulfonylaminocarboxylic acid N-arylamides, their preparation, their use and pharmaceutical preparations comprising them | GUCY1A1, GUCY1B1, GUCY1A2 | KMT2A 4203/4885MEN1 3056/4885MAPT 4873/4885 |
| US-10189809-B2 | SGC stimulators | GUCY1A1, PTGIS, GUCY1B1 | KMT2A 4149/4885MEN1 3461/4885MAPT 4837/4885 |
| US-20230381153-A1 | TREATMENT OF CNS DISEASES WITH sGC STIMULATORS | GUCY1A2, GUCY1B2, PDE2A | KMT2A 3687/4885MEN1 1983/4885MAPT 3160/4885 |
| US-20140288079-A1 | SGC STIMULATORS OF SGC ACTIVATORS IN COMBINATION WITH PDE5 INHBITORS FOR THE TREATMENT OF ERECTILE DYSFUNCTION | PDE5A, PDE3B, PDE3A | KMT2A 3465/4885MEN1 3180/4885MAPT 4395/4885 |
| US-10844064-B2 | sGC stimulators | GUCY1B1, GUCY1A1, PRKG1 | KMT2A 2901/4885MEN1 3638/4885MAPT 4862/4885 |
| US-20130123354-A1 | SOLUBLE GUANYLATE CYCLASE (SGC) MODULATORS FOR TREATMENT OF LIPID RELATED DISORDERS | GUCY1A2, GUCY1B2, GUCY1B1 | KMT2A 3747/4885MEN1 3134/4885MAPT 3732/4885 |
| US-20190125709-A1 | STIMULATORS AND/OR ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE (SGC) IN COMBINATION WITH AN INHIBITOR OF NEUTRAL ENDOPEPTIDASE (NEP INHIBITOR) AND/OR AN ANGIOTENSIN AII ANTAGONIST AND THE USE THEREOF | MME, ECE1, REN | KMT2A 4141/4885MEN1 3303/4885MAPT 3217/4885 |
| US-10183021-B2 | sGC stimulators | PTGIS, CGAS, GUCY1A1 | KMT2A 4250/4885MEN1 2447/4885MAPT 4849/4885 |
| US-10927136-B2 | Phosphorus prodrugs of pyrazolo-substituted pyrimidine sGC stimulators | P2RY1, P2RY11, GMPS | KMT2A 3918/4885MEN1 2409/4885MAPT 4814/4885 |
| US-10189856-B2 | Use of sGC stimulators, sGC activators, alone and combinations with PDE5 inhibitors for the treatment of systemic sclerosis (SSc) | PDE5A, PDE3A, PDE2A | KMT2A 4014/4885MEN1 4136/4885MAPT 4846/4885 |
| US-11572358-B2 | Solid forms of an sGC stimulator | GUCY1A2, PRKG1, GUCY1A1 | KMT2A 4389/4885MEN1 2771/4885MAPT 4405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.